Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin Dreesen
Ann Gils

Showing results (1-10 of 244) with videos related to

Pageof 25
Sort By:
Therapeutic Drug Monitoring|March 19, 2019
Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory DiseasesErwin Dreesen, Ann Gils
Journal of Crohn'S & Colitis|March 24, 2017
Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?Erwin Dreesen, Ann Gils
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 30, 2019
ReplyErwin Dreesen, Ann Gils
Alimentary Pharmacology & Therapeutics|October 16, 2018
Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' replyErwin Dreesen, Ann Gils
Current Drug Targets|March 9, 2016
Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized TreatmentErwin Dreesen, Ann Gils, Severine Vermeire
Clinical Pharmacology : Advances and Applications|October 19, 2017
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseasesErwin Dreesen, Peter Bossuyt, Denis Mulleman, et al.
British Journal of Clinical Pharmacology|May 17, 2020
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's diseaseErwin Dreesen, Sophie Berends, David Laharie, et al.
Inflammatory Bowel Diseases|March 9, 2016
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical SamplesAnn Gils, Thomas Van Stappen, Erwin Dreesen, et al.
British Journal of Clinical Pharmacology|January 12, 2019
Optimising infliximab induction dosing for patients with ulcerative colitisErwin Dreesen, Ruben Faelens, Gert Van Assche, et al.
Journal of Crohn'S & Colitis|September 22, 2018
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Pageof 25

Showing results (1-10 of 244) with videos related to

Sort By:
Pageof 25
Therapeutic Drug Monitoring|March 19, 2019
Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory DiseasesErwin Dreesen, Ann Gils
Journal of Crohn'S & Colitis|March 24, 2017
Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?Erwin Dreesen, Ann Gils
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 30, 2019
ReplyErwin Dreesen, Ann Gils
Alimentary Pharmacology & Therapeutics|October 16, 2018
Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' replyErwin Dreesen, Ann Gils
Current Drug Targets|March 9, 2016
Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized TreatmentErwin Dreesen, Ann Gils, Severine Vermeire
Clinical Pharmacology : Advances and Applications|October 19, 2017
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseasesErwin Dreesen, Peter Bossuyt, Denis Mulleman, et al.
British Journal of Clinical Pharmacology|May 17, 2020
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's diseaseErwin Dreesen, Sophie Berends, David Laharie, et al.
Inflammatory Bowel Diseases|March 9, 2016
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical SamplesAnn Gils, Thomas Van Stappen, Erwin Dreesen, et al.
British Journal of Clinical Pharmacology|January 12, 2019
Optimising infliximab induction dosing for patients with ulcerative colitisErwin Dreesen, Ruben Faelens, Gert Van Assche, et al.
Journal of Crohn'S & Colitis|September 22, 2018
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Pageof 25